Bioarchitects Without Limits

Synthetic, Personalized, Rejuvenated Livers to Cure Cirrhosis

Khufu Therapeutics is pioneering the first approach that permanently restores liver mass, architecture, and function in cirrhosis patients—without transplantation, donor organs, or immunosuppression.

Our founder, Dr. Natesh Parashurama, MD PhD, an MIT-, Harvard-, Stanford-, and UCSF-trained surgeon and bioengineer, spent nearly two decades uncovering the cellular and developmental mechanisms that allow the liver to grow and repair itself. His vision was simple yet transformative: to rebuild the liver from within, using the patient’s own cells.

This vision led to the creation of the Synthetic, Personalized, Rejuvenated (SPR) Platform—a first-in-class technology that integrates stem cell biology, organ engineering, and AI-driven computational modeling to regenerate functional liver tissue directly inside the body.

Khufu Therapeutics offers the only approach that permanently restores liver mass, architecture, and function in cirrhosis patients without transplantation or reliance on adult hepatocytes.

Our mission is clear:

To restore hope and health to patients with liver disease by rebuilding what medicine has never been able to replace—true liver mass, structure, and function.

ABOUT

THE PROBLEM

Cirrhosis is a global epidemic hiding in plain sight.

Over 4 million Americans and 100 million people worldwide are living with end-stage liver disease, yet fewer than 0.25% receive a transplant each year. Every other patient is left to manage symptoms while their liver slowly fails.

Unlike other organs, the liver cannot be replaced or supported by machines or drugs. Once cirrhosis sets in, the organ’s architecture collapses—hepatocytes die, scar tissue replaces healthy tissue, and function disappears.

For 20 years, major pharmaceutical and biotech companies have tried and failed to reverse cirrhosis:

Drugs target inflammation or fibrosis but cannot rebuild lost tissue.
Devices and bioreactors provide only temporary support.
Transplants are scarce, costly, and require lifelong immunosuppression.
iPSC-hepatocyte and 3D-printed approaches fall short in restoring full liver mass or function.

The result is a devastating human and financial toll: millions dying without options, billions spent on palliative care, and no scalable cure in sight.